Gold prices dip as hawkish Fed minutes weigh ahead of Jackson Hole
GAITHERSBURG, Md. - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), a specialty pharmaceutical company specializing in radiation therapy improvements for cancer patients, announced significant progress in its clinical and diagnostic developments. With a current market capitalization of $2.21 million, the micro-cap biotech company reported accelerated enrollment in its Phase 2 clinical trial of Ropidoxuridine, a treatment for glioblastoma patients, with 40% of the initial randomized portion completed as of today. According to InvestingPro analysis, the company faces financial challenges with a current ratio of 0.22, indicating potential liquidity concerns.
The trial, which includes 16 out of a planned 40 patients, is being conducted at several nationally recognized cancer centers. These centers include Georgetown University Medical (TASE:BLWV) Center and Miami Cancer Institute, among others. Shuttle Pharma’s CEO, Dr. Anatoly Dritschilo, expressed optimism about the potential impact of radiation sensitizers on cancer cure rates and patient quality of life. For detailed financial analysis and additional insights, investors can access 10+ more exclusive tips on InvestingPro.
In addition to the clinical trial, Shuttle Pharma’s Diagnostics subsidiary has entered into a research agreement with the University of California, San Francisco to develop a ligand for prostate-specific membrane antigen (PSMA). This molecule could serve both diagnostic and therapeutic purposes for cancer treatment, a concept known as theranostics.
Shuttle Pharma has also launched a new corporate website, showcasing its dual focus on Cancer Therapeutics and Diagnostics. The company’s mission is to enhance the effectiveness of radiation therapy while minimizing side effects for cancer patients.
The company’s advancements over the past year include significant investments by management, with CEO Dr. Dritschilo contributing $237,500 in a recent financing transaction. The company’s stock, currently trading at $0.61, has experienced significant pressure, declining nearly 30% year-to-date and trading close to its 52-week low of $0.58. Shuttle Pharma aims to complete enrollment in the Ropidoxuridine trial within the next year and continues to develop diagnostic tools such as the PC-Rad test for prostate cancer and the PSMA-B ligand for metastatic prostate cancer.
The company’s Annual Report on Form 10-K for the year ended December 31, 2024, was filed with the SEC on February 26, 2025. Financial data reveals an EBITDA of -$7.2 million for the last twelve months, highlighting the company’s current development stage status. The report includes forward-looking statements regarding the company’s development and potential future results, which are subject to various important factors and risks as outlined in the "Risk Factors" section of the report.
This update is based on a press release statement from Shuttle Pharmaceuticals Holdings, Inc.
In other recent news, Shuttle Pharmaceuticals Holdings, Inc. has made significant advancements in its Phase 2 clinical trial for glioblastoma treatment. The company has amended its agreement with Theradex Systems, Inc. to expand the clinical trial of Ropidoxuridine, a drug aimed at improving radiation therapy effectiveness. This amendment includes increasing the patient count from 15 to 16 and expanding the number of trial sites from four to six. Additionally, Shuttle Pharmaceuticals has achieved a milestone by enrolling 25% of participants in the initial randomized segment of the study, which involves 40 patients divided into two groups receiving different dosages of Ropidoxuridine. The trial aims to determine the optimal dose to enhance survival rates among patients with IDH wild-type, methylation-negative glioblastoma. The company has received Orphan Drug Designation from the FDA, underscoring its commitment to advancing cancer treatment. Shuttle Pharmaceuticals continues to conduct the trial at several renowned cancer centers across the United States, emphasizing its dedication to improving patient outcomes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.